Company Filing History:
Years Active: 2019
Title: Innovations of Yu-Ling Chang in Cancer Treatment
Introduction
Yu-Ling Chang is a prominent inventor based in Taipei, Taiwan. She has made significant contributions to the field of cancer research, particularly through her innovative work on antibodies that target specific receptors involved in tumor growth.
Latest Patents
Yu-Ling Chang holds a patent for an "Anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody and methods of use thereof for detecting VEGFR2 and for inhibiting tumor growth, tumor angiogenesis and/or inducing cancer cell cytotoxicity." This patent describes an isolated antibody or an antigen-binding fragment that specifically binds to an epitope within the domain 1 or domain 3 of human VEGFR2. The epitope within domain 3 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. The patent also outlines the use of this antibody in the manufacture of a medicament aimed at inhibiting tumor growth and inducing cancer cell cytotoxicity in patients.
Career Highlights
Yu-Ling Chang is affiliated with Academia Sinica, where she conducts her research and development activities. Her work has been instrumental in advancing the understanding of VEGFR2 and its role in cancer progression.
Collaborations
Some of her notable coworkers include Han-Chung Wu and Ruei-Min Lu, who have collaborated with her on various research projects.
Conclusion
Yu-Ling Chang's innovative work in developing targeted therapies for cancer demonstrates her commitment to advancing medical science. Her contributions are paving the way for new treatment options for patients in need.